UCSF Cancer Specialists to Present Clinical Findings at Major Conference 

2022 ASCO Annual Meeting Focuses on New Treatment Options

By Elizabeth Fernandez | UCSF.edu | June 02, 2022


The latest advances in cancer care and research will be showcased at the annual American Society of Clinical Oncology (ASCO) Annual Meeting, the world’s largest clinical cancer meeting.

More than 30,000 oncology professionals from around the world are expected to attend in person in Chicago or virtually June 3-7. The theme this year is Advancing Equitable Cancer Care Through Innovation.

The annual gathering will feature new treatment options for patients with breast, pancreatic, head and neck, gynecologic, colorectal or other forms of cancer. More than 5,000 abstracts were selected for this year’s meeting – about 2,800 to be presented at the conference, and some 2,220 accepted for online application.

At last year’s session, about a dozen countries were represented, including clinical oncologists, researchers, radiation oncologists, medical residents, pharmacists and patient advocates.

“ASCO is one of the most important medical meetings in the world, and it is critical for oncology specialists to share information with each other on research and innovation,” said Alan Ashworth, PhD, FRS, president of the UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) and senior vice president for cancer services with UCSF Health. “We look forward to sharing insights and perspectives from UCSF, home to some of oncology’s finest clinicians and scientists.” 

Here are some of the featured presentations by UCSF:

Equity in the workplace: Ana Velazquez Manana, MD

Equity in the workplace: Ana Velazquez Manana, MD, will take part in a panel session entitled “Microaggression, Bias and Equity in the Workplace” on Friday, June 3. The discussion will include a review of evidence “on why promoting equity in our workplace is imperative for us as members of the healthcare community,” said Velazquez Manana. Panelists will also describe strategies to promote equity within oncology practices.

“This topic is important for oncology and medicine in general as we have more and more data showing persistent inequities in salary, promotion, and workplace experiences of women, racial/ethnic minorities, and gender minorities in medicine,” she said.

Velazquez Manana is a clinical instructor in medical oncology with the UCSF Division of Hematology and Oncology, and a postdoctoral fellow with the National Clinician Scholars Program at UCSF.


Breast cancer: Hope S. Rugo, MD

Breast cancer: Hope S. Rugo, MD, will present primary results from a major clinical trial, TROPiCS-02, a randomized phase 3 study of the medication sacituzumab govitecan (SG) compared to treatment of a physician’s choice in patients with hormone receptor-positive/HER2-negative advanced breast cancer. This form of cancer occurs in approximately 70 percent of all breast cancer cases.

The session, part of ASCO’s “news of the day” featuring especially important findings, will be held on Saturday, June 4.

Rugo is a UCSF professor of medicine and director of Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family Comprehensive Cancer Center.


Molecular imaging: Thomas A. Hope, MD

Molecular imaging: Thomas A. Hope, MD, is first author of a poster presentation on Sunday, June 5 that describes a promising imaging agent called 68Ga-FAP-2286. The study was a first-in-humans Phase 1/11 study involving 27 patients with solid tumors including bladder cancer, head and neck squamous cell cancer, breast cancer and castration-resistant prostate cancer. The researchers found uptake on some lesions, but the benefit was not equal: breast cancer had the highest uptake while prostate cancer had the lowest.

The researchers said further inquiry may aid clinical decision-making and help determine which patients might benefit the most. Hope is an associate professor at UCSF and director of molecular therapy in the Department of Radiology and Biomedical Imaging. He also serves as chief of nuclear medicine at the San Francisco VA Medical Center.


Gastrointestinal cancer: Andrea Grace Bocobo

Gastrointestinal cancer: Andrea Grace Bocobo will present poster findings June 4 from a Phase II study of some 44 patients that evaluated the safety, tolerability and preliminary efficacy of pembrolizumab in combination with capecitabine and bevacizumab in MSS mCRC.

Bocobo is a fourth-year medical student at Touro University California. The senior author is Chloe Evelyn Atreya, MD, PhD, an associate clinical professor with the HDFCCC who specializes in gastrointestinal cancer. 


Artificial intelligence: Mack Roach III, MD

Artificial intelligence: Mack Roach III, MD, will be part of ASCO’s Clinical Science Symposium on June 6 entitled “Is There a Ghost in the Machine? Putting Artificial Intelligence to Work.” Roach and his team of researchers explain in their abstract that artificial intelligence (AI) tools can display racial bias “as a result of existing systemic health inequities and biased datasets.”

Roach will focus on prostate cancer risk in African American men who were evaluated via digital histopathology multi-modal deep learning models developed on NRG Oncology Phase III clinical trials. The study is believed to be the first comparative analyses of a digital pathology AI prognostic model in African Americans vs. non-African American prostate cancer patients. The researchers found that the prognostic performance of the AI models was comparable between subgroups.

Roach is a professor in the UCSF Departments of Radiation Oncology and Urology, and a member of the HDFCCC. The senior author is Felix Y. Feng, MD, Associate Director for Translational Clinical Research at the HDFCCC and co-leader of the prostate cancer program at UCSF.


Role of DNA in cancer: Alan Ashworth, PhD, FRS

Role of DNA in cancer: Alan Ashworth, PhD, FRS, is a primary speaker in a joint session of ASCO and the American Association for Cancer Research on the DNA damage response and the BRCA genes, which produce proteins that help repair damaged DNA. Ashworth’s session is entitled “The Promise of DNA Damage Response and Repair in Cancer.” The education program will take place Monday, June 6.

“Through a better understanding of DNA repair, we will be able to gain insight into cancer’s complexities, and be able to develop more effective treatments for the disease,” Ashworth said.   

President of UCSF’s HDFCCC, Ashworth is a translational biologist and laboratory researcher whose research centers on understanding breast cancer genetics to improve the treatment and care of patients.


Equitable care in prostate cancer: Hala Borno, MD

Equitable care in prostate cancer: Hala Borno, MD, will take part in an educational session, “Patient-Centered Approaches: Advancing Equitable Prostate Cancer Care Through Innovation.”

The presentation, part of the genitourinary cancer tract, will take place on Monday, June 6.

Borno will discuss community partnerships in prostate cancer care.

Borno is an assistant clinical professor in the UCSF Division of Hematology/Oncology.


Breast Cancer: Laura Ann Huppert, MD

Breast Cancer: Laura Ann Huppert, MD, is conducting an oral abstract presentation on Tuesday, June 7 about hormone receptor positive breast cancer. The study is based on results from the I-SPY 2 national trial, a phase II randomized, adaptive study evaluating multiple investigational agents as neoadjuvant breast cancer therapy. The findings showed pathologic complete response rates for HR+/HER2- breast cancer stratified by Response Predictive Subtypes, suggesting that some signatures are more likely to respond to neoadjuvant therapy, and that an immune signature can identify patients more likely to respond to pembrolizumab.

Huppert is a medical oncology fellow at UCSF. The senior author of the abstract is Laura Esserman, MD, MBA, director of the UCSF Breast Care Center, and founder and co-principal investigator of the I-SPY trials.


Developmental therapeutics: Rahul Raj Aggarwal, MD

Developmental therapeutics: Rahul Raj Aggarwal, MD, is giving an oral abstract presentation on June 7 about a Phase 1a/1b study of FOR46, an antibody drug conjugate targeting CD46 in metastatic castration-resistant prostate cancer.

Aggarwal is Associate Director for Clinical Sciences at the HDFCCC and an associate professor of Hematology/Oncology at UCSF. He is the first author of the abstract. The senior author is Eric Jay Small, MD, a professor in residence of medicine and urology at UCSF, and co-leader of the prostate cancer program.



Presentations by Day

FRIDAY, June 3 


SUNDAY, June 5 

MONDAY, June 6

TUESDAY, June 7 

Additional Posters & Discussion (UCSF First Authors)

  • Poster Discussion Session | Sam Brondfield, Matthew Schwede, Tyler Paul Johnson, Shagun Arora | Online scaffolds: A constructivist approach to oncology fellow learning. | https://meetings.asco.org/abstracts-presentations/209197/
  • Poster Discussion Session | Hope S. Rugo, Joyce O'Shaughnessy, Komal L. Jhaveri, Sara M. Tolaney, Fatima Cardoso, Aditya Bardia, Vikalp Kumar Maheshwari, Sandeep Tripathi, Purnima Pathak, Sina Haftchenary, Peter A. Fasching | Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/human epidermal growth factor receptor–negative (HR+/HER2−) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC). | https://meetings.asco.org/abstracts-presentations/208059/
  • Poster Discussion Session | Kieuhoa Tran Vo, Amit J. Sabnis, Paul M. Williams, Sinchita Roy-Chowdhuri, David R. Patton, Brent Coffey, Joel M. Reid, Jin Piao, Lauren Saguilig, Todd Allen Alonzo, Stacey L. Berg, Alok Jaju, Elizabeth Fox, Douglas S. Hawkins, Margaret M. Mooney, Naoko Takebe, James V. Tricoli, Katherine A. Janeway, Nita Seibel, Donald Williams Parsons | Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J). | https://meetings.asco.org/abstracts-presentations/209223/
  • Poster Discussion Session | Hyunseok Kang, Myung-Ju Ahn, Jameel Muzaffar, Bhumsuk Keam, Daniel W. Bowles, Deborah J.L. Wong, Alan Loh Ho, Sung-Bae Kim, Francis P. Worden, Tak Yun, Suha Sari, Maureen G Conlan, Glenn J. Hanna | A phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, rivoceranib, for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC). | https://meetings.asco.org/abstracts-presentations/207049/
  • Poster Session | Laura Ann Huppert, Zak Walker, Moming Li, Mi-Ok Kim, Jennie Callan, Melanie Majure, Michelle E. Melisko, Hope S. Rugo, Spencer Behr, Amy Jo Chien | Clinical and radiographic characteristics of patients with metastatic breast cancer and pseudocirrhosis: A single-center retrospective cohort study. | https://meetings.asco.org/abstracts-presentations/210251/
  • Poster Session | Luke Kim, Evelin Trejo, Dame Idossa, Narjust Duma, Ana I. Velazquez Manana | Quality and content of online cancer information: An analysis of NCI-designated cancer center YouTube videos. | https://meetings.asco.org/abstracts-presentations/210044/
  • Poster Session | Jaeyoon Cha, Paige Warner, Robert Hiatt, Scarlett Lin Gomez, Laura van 't Veer, Allison Stover-Fiscalini, Alexander Borowsky, W. Fraser Fraser Symmans, Denise M. Wolf, Christina Yau, Douglas Yee, Angela DeMichele, Donald A. Berry, Laura Esserman, William M. Audeh, Shraddha Modh | Distribution of breast cancer molecular subtypes within receptor classifications: Lessons from the I-SPY2 Trial and FLEX Registry. | https://meetings.asco.org/abstracts-presentations/210725/
  • Poster Session | Thomas A. Hope, Rahul Raj Aggarwal, Mallika Sachdev Dhawan, Robin Kate Kelley, Robert R. Flavell, Courtney Lawhn Heath, Yan Li, Sima P. Porten, Hope S. Rugo, Sue S. Yom, Robin Ippisch, Vadim S Koshkin | Imaging of solid tumors using 68Ga-FAP-2286. | https://meetings.asco.org/abstracts-presentations/210932/
  • Poster Session | Sam Brondfield, Katherine Hyland, Patricia A. Cornett, Heidi Kirsch | Applying cognitive integration to oncology: A novel asynchronous foundational science curriculum for medical students during clerkships. | https://meetings.asco.org/abstracts-presentations/209799/
  • Poster Session | Jacob S Young, Nam Woo Cho, Ti Casey-Clyde, Raquel Santos, Kyounghee Seo, Joanna J. Phillips, Mitchel S. Berger, Tomoko Ozawa, David R. Raleigh | Convection-delivered adenoviral gene therapy reprograms the immunosuppressive glioblastoma microenvironment. | https://meetings.asco.org/abstracts-presentations/208744/
  • Poster Session | Robin Kate Kelley, Eric Van Cutsem, Michael Sangmin Lee, Ido Wolf, Marwan Fakih, Judith de de Vos-Geelen, Valerie Lee, Arndt Vogel, Larry Wu, Fan Jin, Girish S. Naik, Eileen Mary O'Reilly | Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors. | https://meetings.asco.org/abstracts-presentations/213328/
  • Poster Session | Dame Idossa, Ana I. Velazquez Manana, Miki Horiguchi, Julia Alberth, Inas Abuali, Demetria Joy Smith-Graziani, Gilberto Lopes, Sam Joseph Lubner, Narjust Duma | Are we doing it right? Mentorship challenges for oncology fellows and early-career faculty from backgrounds underrepresented in medicine. | https://meetings.asco.org/abstracts-presentations/209944/
  • Poster Session | Mazie Tsang, Kara E. Bischoff, Kelly L. Schoenbeck, Kim Berry, David O'Riordan, Bita Fakhri, Sandy Wai Kuan Wong, Nina Shah, Eve Cohen, Nancy Shepard Lopez, Gabriel N. Mannis, Michael W. Rabow | Embedded outpatient palliative care for hematologic malignancies: Referral patterns and health care utilization. | https://meetings.asco.org/abstracts-presentations/211481/
  • Poster Session | Erica S Tsang, Rahul Raj Aggarwal, Scott Thomas, Mallika Sachdev Dhawan, Nela Pawlowska, Imke Heleen Bartelink, Jennifer A. Grabowsky, Thierry Marie Jahan, Thach-Giao Truong, Charles J. Ryan, Pamela N. Munster | Updated survival follow-up for phase I study of abexinostat with pazopanib in patients with solid tumor malignancies. | https://meetings.asco.org/abstracts-presentations/210777/
  • Poster Session | Hope S. Rugo, Javier Cortes, Binghe Xu, Chiun-Sheng Huang, Sung-Bae Kim, Michelle E. Melisko, Rita Nanda, Priyanka Sharma, Richard Schwab, Pei Hsu | A phase 3, randomized, open-label study of the anti-Globo H vaccine adagloxad simolenin/obi-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer. | https://meetings.asco.org/abstracts-presentations/213351/
  • Poster Session | Francis Wright, Daniel Myung Kim, Jordyn Silverstein, Michelle Wang, Kimberly de Dios, Arabella Young, Zoe E. Quandt, Sam Brondfield | Evaluating survival following severe immune-related adverse events requiring hospitalization. | https://meetings.asco.org/abstracts-presentations/210210/
  • Poster Session | Andrew Hwang, Jason Doornenbal, Daniel Park, Inderpreet Bal, Mohammed SANI Bukari, Yueqi Yan, Haifaa Abdulhaq | Clinicopathological characteristics of high-risk multiple myeloma in Hispanic versus non-Hispanic patients in central California. | https://meetings.asco.org/abstracts-presentations/207907/
  • Poster Session | Hope S. Rugo, Joohyuk Sohn, Yolanda Jerez Gilarranz, Lucia Gonzalez-Cortijo, Amir Sonnenblick, Dhanusha Sabanathan, Ernesto Pablo Korbenfeld, Daniel Egle, Brigitte Poirier, Flora Zagouri, Alexios Matikas, Sercan Aksoy, Umut Demirci, Pier Ramos-Elias, Seock-Ah Im, Fatima Cardoso, Liyi Jia, Carlos Baccan, Konstantinos Tryfonidis, Peter Schmid | KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer. | https://meetings.asco.org/abstracts-presentations/213426/
  • Poster Session | Evan Justin Walker, Erkut Hasan Borazanci, Gehan Botrus, Christos Fountzilas, J. Randolph Hecht, Anup Kasi, Niharika B. Mettu, Shubham Pant, Glenn Michelson, Gene Cho, Sangsook Ahn Cho, Lorna Liganor, Andrew H. Ko | A phase 1b/2, dose-escalation, randomized, multicenter study of maintenance (maint) ivaltinostat (ival) plus capecitabine (cap) or capecitabine monotherapy in patients (pts) with metastatic pancreatic adenocarcinoma (PDAC) whose disease has not progressed on first-line FOLFIRINOX chemotherapy (CT). | https://meetings.asco.org/abstracts-presentations/213168/
  • Poster Session | Andrea Grace Bocobo, Renee Wang, Spencer Behr, Julia C. Carnevale, Pelin Cinar, Eric Andrew Collisson, Lawrence Fong, Bridget P Keenan, Wesley Allen Kidder, Andrew H. Ko, Kanti Pallav Kolli, Megan Kennedy, Angela Laffan, Sorbarikor Piawah, Marin Pollak, Gabriel Schwartz, Julia Whitman, Li Zhang, Katherine Van Loon, Chloe Evelyn Atreya | Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). | https://meetings.asco.org/abstracts-presentations/208507/
  • Poster Session | Thomas G. Martin, Philippe Moreau, Saad Zafar Usmani, Alfred L. Garfall, Maria-Victoria Mateos, Jesús F. San-Miguel, Albert Oriol Rocafiguera, Ajay K. Nooka, Laura Rosiñol, Ajai Chari, Lionel Karlin, Amrita Y. Krishnan, Nizar J. Bahlis, Rakesh Popat, Britta Besemer, Joaquin Martinez, Michel Delforge, John Fastenau, Katharine S. Gries, Niels W.C.J. van de Donk | Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1. | https://meetings.asco.org/abstracts-presentations/207903/
  • Publication Only | Ana I. Velazquez Manana, Hala Borno, Evelin Trejo, Sylvia Zhang, Abigail A. Rodriguez Saldana, Ivan C. Leung, Hilary K. Seligman, Tracy Kuo Lin | Evaluating predictors of food insecurity among patients with cancer in the safety-net setting. | https://meetings.asco.org/abstracts-presentations/206367/
  • Publication Only | Sheyla P Medina, Sylvia Zhang, Elena Nieves, Dana Dornsife, Robert G. Johnson, Darcy V. Spicer, Hala Borno | Measuring the long commute: Experiences of a multi-ethnic cohort of patients enrolled in a financial reimbursement program for cancer clinical trials. | https://meetings.asco.org/abstracts-presentations/206257/
  • Publication Only | Ana I. Velazquez Manana, Dame Idossa, Kelly Jasmin Meza, Juan J. Rodriguez Vargas, Narjust Duma | Are we providing adequate information? patient-specific clinical trial information at NCI-designated cancer center websites. | https://meetings.asco.org/abstracts-presentations/206592/
  • Publication Only | Niharika Dixit, Ana I. Velazquez Manana, Kelly Gordon, Ivan C. Leung, Terence W. Friedlander, Miya Frick, Evelin Trejo, Kendall Levine, Rebecca Jane DeBoer, Robin Lee, Judy M. Cheng, Paul Couey, Chia-Ching Jackie Wang, Galen Joseph | Implementation of a “genetic testing station” in a safety net hospital to optimize access and increase equity. | https://meetings.asco.org/abstracts-presentations/206307/
  • Publication Only | Kieuhoa Tran Vo, Katherine K. Matthay, Susan G. Groshen, Yueh-Yun Chi, Meaghan Granger, Julie R. Park, Araz Marachelian, Steven G. DuBois | Clinical and biologic predictors of response to MIBG therapy: A report from the new approaches to neuroblastoma therapy (NANT) consortium. | https://meetings.asco.org/abstracts-presentations/209412/
  • Publication Only | Katie Lichter, Sasha Demeulenaere, Taylor Drew, Emily Wong, Surbhi Grover | The reduced environmental impact of American society of Clinical Oncology’s 2021 virtual annual meeting. | https://meetings.asco.org/abstracts-presentations/212738/
  • Publication Only | Miranda Craft, Christopher Craggs, Nayia Ravel, John K Chan, Yvonne Gail Lin | Real-world use of PD-(L)1 immune checkpoint inhibitors (CPI) and post-CPI treatment patterns and outcomes in ovarian and endometrial cancer (2014-2021). | https://meetings.asco.org/abstracts-presentations/206362/
Read more at UCSF.edu